The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.
The GENESIS study is a multicenter, prospective, non-interventional, clinical study with a target of 12,000 subjects and an anticipated total duration of 36 months. The aim of study GENESIS is to provide a pilot map of HLA genetic variation in the Greek population in order to be used in medical research and for possible clinical applications (evaluation of possible correlations with selected underlying diseases). During the study, each subject will conduct one visit to the participating cite, in which they will provide: 1. Demographic information \[i.e. date of birth, gender, race, ancestry (including information about the subject's grandparents' birthplace), height, weight\], 2. Other information about smoking/vaping, alcohol consumption, arterial blood pressure, diagnosed diseases (if any), current treatments (if any), and 3. Recent (up to 12 months prior to sample collection) results if/when are available from clinical lab tests such as blood count (Hct, Hb, RBC, WBC, PLT count), including a metabolic panel, liver enzymes and biochemical parameters (Glu, HbA1c, TC, TG, LDL-C, HDL-C, ALT, AST, ALP, γGT, bilirubin, LDH, insulin, C-peptide). Upon completion of the data registry, two buccal swabs will be collected per subject and they will be stored at ALTP premises until their shipment to Galatea.Bio. All buccal swab samples will be subjected to genetic material (DNA) extraction. The DNA samples will be further proceeded for HLA genotyping analysis. A follow up analysis will be performed in selected DNA samples via full low-pass whole genome sequencing (LP-WGS), which aims to further investigate the association between the HLA region and autoimmune diseases. Upon completion of the analysis, an individualized ancestry report will be securely made available to all study subjects which they can access, as and if they elect to.
Study Type
OBSERVATIONAL
Enrollment
12,000
2nd Propaedeutic Department of Internal Medicine, Attikon University General Hospital
Chaïdári, Attica, Greece
NOT_YET_RECRUITING2nd Department of Neurology, AHEPA University Hospital
Thessaloniki, Thessaloniki, Greece
NOT_YET_RECRUITINGDepartment of Respiratory Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Thrace, Greece
RECRUITINGDepartment of Infectious Diseases, 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Greece
RECRUITINGDepartment of Cardiology, University General Hospital of Heraklion
Heraklion, Greece
NOT_YET_RECRUITINGDepartment of Rheumatology, University Hospital of Heraklion
Heraklion, Greece
NOT_YET_RECRUITINGDepartment of Respiratory, University Hospital of Ioannina
Ioannina, Greece
RECRUITINGDepartment of Haematology, University General Hospital of Larissa
Larissa, Greece
NOT_YET_RECRUITINGAllele frequency of HLA-alleles at the Greek population level
To assess the HLA allelic diversity of Greek population
Time frame: 36th month
Prevalence of selected HLA-related diseases in the Greek population
Characterization of the allelic and haplotypic HLA frequency distribution in the Greek population and comparison with global HLA databases.
Time frame: 36th month
Relative Risk (Risk Ratio (RR) or Odds Ratio (OR)) of HLA markers on diseases of interest
Evaluation of the association between HLA alleles and/or haplotypes, and selected diseases
Time frame: 36th month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.